Literature DB >> 16867910

Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.

Chihiro Shimazaki, Yutaka Kobayashi, Tohru Inaba, Masafumi Taniwaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16867910     DOI： 10.1532/IJH97.06062

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  6 in total

1.  High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.

Authors:  C Shimazaki; R Uchida; S Nakano; K Namura; S-i Fuchida; A Okano; M Okamoto; T Inaba
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

2.  Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

Authors:  Shigesaburo Miyakoshi; Masahiro Kami; Koichiro Yuji; Tomoko Matsumura; Masaaki Takatoku; Makoto Sasaki; Hiroto Narimatsu; Takeshi Fujii; Masateru Kawabata; Shuichi Taniguchi; Keiya Ozawa; Kazuo Oshimi
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

Review 4.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

6.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245
  6 in total
  3 in total

1.  Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.

Authors:  Shuji Ozaki; Osamu Tanaka; Shiro Fujii; Yuri Shigekiyo; Hirokazu Miki; Masahito Choraku; Kumiko Kagawa; Jin Asano; Kyoko Takeuchi; Ken-ichi Kitazoe; Toshihiro Hashimoto; Masahiro Abe; Toshio Matsumoto
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 2.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

3.  Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia.

Authors:  Ingrid M Wirth; Gregory E Peters
Journal:  Respir Med Case Rep       Date:  2020-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.